DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.
Tools I Use
Real-Time Market Scanner
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Recommended Platform
Professional Trading Workflow
Charts • Watchlists • Multi-broker tools
Built for active traders
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
⚠️ IMPORTANT NOTICE / AVVISO IMPORTANTE:
This document is a news digest and company profile compiled from publicly available sources (SEC filings, press releases, official company announcements). It is NOT investment advice, NOT a recommendation to buy or sell, and does NOT constitute a solicitation of any kind. The author is NOT a licensed financial advisor. Always conduct your own due diligence and consult a qualified professional before making any financial decisions.
Questo documento è un digest di notizie e profilo aziendale compilato da fonti pubbliche (SEC filing, comunicati stampa, annunci ufficiali). NON è un consiglio di investimento, NON è una raccomandazione di acquisto o vendita, e NON costituisce sollecitazione di alcun tipo. L'autore NON è un consulente finanziario autorizzato. Effettua sempre la tua due diligence e consulta un professionista qualificato prima di prendere decisioni finanziarie.
This document is a news digest and company profile compiled from publicly available sources (SEC filings, press releases, official company announcements). It is NOT investment advice, NOT a recommendation to buy or sell, and does NOT constitute a solicitation of any kind. The author is NOT a licensed financial advisor. Always conduct your own due diligence and consult a qualified professional before making any financial decisions.
Questo documento è un digest di notizie e profilo aziendale compilato da fonti pubbliche (SEC filing, comunicati stampa, annunci ufficiali). NON è un consiglio di investimento, NON è una raccomandazione di acquisto o vendita, e NON costituisce sollecitazione di alcun tipo. L'autore NON è un consulente finanziario autorizzato. Effettua sempre la tua due diligence e consulta un professionista qualificato prima di prendere decisioni finanziarie.
?? English Version
? NRx Pharmaceuticals (NRXP)
Company Profile & News Digest — CNS Biotech: Ketamine & Suicidal Depression
Update: November 26, 2025
? MULTIPLE FDA CATALYSTS Q4 2025
✓ ANDA "No Significant Deficiencies"
✓ Breakthrough Therapy
✓ Fast Track
NASDAQ: NRXP | Price: ~$2.18 | Market Cap: ~$60M | YTD: +162% | 52-Week: $0.82 - $5.80
? NRx Pharmaceuticals (NRXP) — Multi-Catalyst CNS Play: NRX-100, NRX-101, KETAFREE™ FDA Submissions Q4 2025 / H1 2026
? RECENT NEWS HIGHLIGHTS: NRx has three FDA submission pathways converging in Q4 2025:
- Nov 6, 2025: FDA confirms ANDA re-filing has "no significant deficiencies"
- NRX-100 NDA: PDUFA target before Dec 31, 2025
- NRX-101 NDA: Rolling review under Breakthrough Therapy
- KETAFREE™ ANDA: Priority Review requested
Table of Contents
1. Company Overview
NRx Pharmaceuticals is a clinical-stage CNS biotech focused on NMDA receptor-modulating therapeutics for suicidal depression, bipolar disorder, chronic pain, and PTSD. The company has two lead drug candidates in advanced regulatory submissions.
? Key Developments (From Official Sources):
- Three separate regulatory pathways (2 NDAs + 1 ANDA) currently active
- FDA confirmed "no significant deficiencies" on ANDA (Nov 6, 2025)
- NRX-101 has Breakthrough Therapy Designation; NRX-100 has expanded Fast Track
- HOPE clinics generating first revenue ($242K in Q3 2025)
- No FDA-approved treatment for suicidal depression currently exists
2. Pipeline Status
? NRX-100 (Preservative-Free IV Ketamine)
NDA Filing ANDA Filed Fast TrackIndication: Suicidal Ideation in Depression (including Bipolar Depression)
Mechanism: NMDA receptor modulator — rapid-acting antidepressant effect
Key Differentiator: PRESERVATIVE-FREE formulation (eliminates benzethonium chloride)
Regulatory Status (per company filings):
- NDA: Filing in progress; PDUFA target before Dec 31, 2025
- ANDA (KETAFREE™): Re-filed Sept 29, 2025; FDA confirmed "no significant deficiencies" Nov 6, 2025
- Fee Waiver: $4.3M NDA submission fee waived by FDA
? NRX-101 (D-Cycloserine + Lurasidone)
NDA Rolling Review Breakthrough TherapyIndication: Suicidal Treatment-Resistant Bipolar Depression
Mechanism: Oral fixed-dose combination maintaining ketamine's neuroplasticity benefits
Regulatory Status:
- NDA: Module 3 (manufacturing) submitted; rolling review under Breakthrough
- PDUFA: Company targets before year-end 2025
3. FDA Timeline (Official Announcements)
? Nov 6, 2025 — ANDA Status Update
FDA confirmed KETAFREE™ ANDA has "no significant deficiencies"
Source: Company press release. Priority Review requested.
? Q4 2025 — NRX-100 NDA PDUFA
Company states PDUFA target date before December 31, 2025
NDA for preservative-free ketamine. Fast Track designation. $4.3M filing fee waived.
? Q4 2025 — NRX-101 NDA Rolling Review
Breakthrough Therapy designation enables rolling review
Module 3 submitted per company announcement.
? H1 2026 — KETAFREE™ ANDA (Company Target)
Company anticipates potential approval mid-2026
Based on "no significant deficiencies" confirmation.
? 2026+ — HOPE Network Expansion
Ongoing clinic acquisitions announced
ONE-D Protocol launched Nov 10, 2025 (first in Florida).
4. HOPE Therapeutics Subsidiary
NRx operates HOPE Therapeutics, a subsidiary running interventional psychiatry clinics offering ketamine infusions, TMS, Spravato®, and other treatments.
| Milestone | Date | Detail |
|---|---|---|
| Dura Medical Acquisition | Sept 8, 2025 | Naples & Ft. Myers, FL clinics acquired |
| First Revenue | Q3 2025 | $242,000 patient service revenue |
| Cohen & Associates | Oct 2025 | Sarasota FL clinic added |
| ONE-D Protocol Launch | Nov 10, 2025 | Company reports 87% response, 72% remission |
5. Financial Data (SEC Filings Q3 2025)
5.1 Income Statement
| Item ($M) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Patient Service Revenue | $0.24 | $0.00 | $0.24 | $0.00 |
| R&D Expenses | $1.8 | $2.1 | $5.2 | $7.5 |
| SG&A Expenses | $3.5 | $3.0 | $10.4 | $10.1 |
| Net Loss | ($5.7) | ($5.0) | ($28.9) | ($17.3) |
5.2 Balance Sheet (September 30, 2025)
| Item | Sep 30, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash & Equivalents | $7.1M | $5.9M |
| Subscription Receivable | $3.2M | — |
| Total Assets | $15.0M | $9.0M |
| Total Liabilities | $40.8M | $42.9M |
| Stockholders' Deficit | ($25.8M) | ($33.9M) |
| Accumulated Deficit | ($307.3M) | ($278.4M) |
| Shares Outstanding | 27.7M | 14.6M |
6. Target Market Size (Company Estimates)
>$3B
Suicidal Depression
(Company estimate)
(Company estimate)
>$1B
Bipolar Depression
(Company estimate)
(Company estimate)
$750M+
IV Ketamine Market
(Industry estimate)
(Industry estimate)
~48,000
US Suicides/Year
(CDC data)
(CDC data)
7. Risk Factors (From SEC Filings)
The following risks are disclosed in the company's SEC filings:
? Financial Risks
- Going concern warning included in Q3 2025 10-Q
- Negative stockholders' equity of ($25.8M)
- Shares nearly doubled in 2025 (14.6M → 27.7M)
- Significant warrant and convertible note liabilities
- Management states cash runway through Q2 2026 only
? Regulatory Risks
- FDA could request additional data or issue Complete Response Letter
- NDA approvals are not guaranteed even with Breakthrough/Fast Track
- Competitive products (Spravato®, generics) already on market
? Execution Risks
- HOPE clinic integration and scaling requires execution
- Commercial infrastructure for drug launch not yet built
- Competition from established players
8. Possible Outcomes
Based on publicly available information, the following scenarios are theoretically possible. This is NOT a prediction or recommendation.
? Positive Scenario
One or more FDA approvals in Q4 2025 / H1 2026; HOPE revenue scales; no major dilution required.
? Neutral Scenario
FDA requests additional data; approvals delayed; company raises additional capital with some dilution; operations continue.
? Negative Scenario
FDA issues CRL on all submissions; significant dilution or going concern issues materialize.
9. Official Sources & SEC Links
SEC Filings
Press Releases (Official)
Company Resources
?? Versione Italiana
? NRx Pharmaceuticals (NRXP)
Profilo Aziendale & Digest Notizie — CNS Biotech: Ketamina e Depressione Suicidaria
Aggiornamento: 26 Novembre 2025
? MULTIPLI CATALYST FDA Q4 2025
✓ ANDA "Nessuna Deficienza Significativa"
✓ Breakthrough Therapy
NASDAQ: NRXP | Prezzo: ~$2.18 | Market Cap: ~$60M | YTD: +162% | 52-Week: $0.82 - $5.80
? NOTIZIE RECENTI: NRx ha tre percorsi regolatori FDA convergenti in Q4 2025:
- 6 Nov 2025: FDA conferma che l'ANDA re-filed "non ha deficienze significative"
- NRX-100 NDA: PDUFA target entro 31 Dicembre 2025
- NRX-101 NDA: Rolling review sotto Breakthrough Therapy
- KETAFREE™ ANDA: Priority Review richiesta
1. Profilo Aziendale
NRx Pharmaceuticals è una biotech CNS clinical-stage focalizzata su terapie modulatrici del recettore NMDA per depressione suicidaria, disturbo bipolare, dolore cronico e PTSD.
2. Status Pipeline
? NRX-100 (Ketamina IV Senza Conservanti)
NDA Filing ANDA Filed Fast TrackIndicazione: Ideazione Suicidaria nella Depressione
Status: NDA in corso; ANDA confermato "no significant deficiencies" 6 Nov 2025
? NRX-101 (D-Cicloserina + Lurasidone)
NDA Rolling Review Breakthrough TherapyIndicazione: Depressione Bipolare Suicidaria Treatment-Resistant
Status: Module 3 sottomesso; rolling review attivo
3. Timeline FDA (Annunci Ufficiali)
? 6 Nov 2025 — ANDA Status
FDA conferma KETAFREE™ ANDA "no significant deficiencies"
? Q4 2025 — NRX-100 NDA PDUFA
Target entro 31 Dicembre 2025 (da annuncio aziendale)
? Q4 2025 — NRX-101 Rolling Review
Breakthrough Therapy designation attivo
4. Dati Finanziari (SEC Q3 2025)
| Voce | 30 Set 2025 | 31 Dic 2024 |
|---|---|---|
| Cash & Equivalents | $7.1M | $5.9M |
| Totale Attività | $15.0M | $9.0M |
| Totale Passività | $40.8M | $42.9M |
| Deficit Azionisti | ($25.8M) | ($33.9M) |
| Azioni in Circolazione | 27.7M | 14.6M |
5. Fattori di Rischio (Da SEC Filing)
? Rischi Finanziari
- Going concern warning nel 10-Q Q3 2025
- Patrimonio netto negativo di ($25.8M)
- Azioni quasi raddoppiate nel 2025 (14.6M → 27.7M)
- Cash runway dichiarato fino a Q2 2026
? Rischi Regolatori
- FDA potrebbe richiedere dati aggiuntivi o emettere CRL
- Approvazioni NDA non garantite anche con Breakthrough/Fast Track
- Competizione da Spravato® e ketamina generica
6. Possibili Scenari
Basandosi su informazioni pubbliche, i seguenti scenari sono teoricamente possibili. Questo NON è una previsione o raccomandazione.
? Scenario Positivo
Una o più approvazioni FDA in Q4 2025 / H1 2026; revenue HOPE scala; nessuna diluizione significativa.
? Scenario Neutro
FDA richiede dati aggiuntivi; approvazioni ritardate; raccolta capitale con diluizione; operazioni continuano.
? Scenario Negativo
FDA emette CRL su tutte le submission; diluizione significativa o problemi di going concern.
7. Fonti Ufficiali e Link SEC
SEC Filing
Comunicati Stampa Ufficiali
Risorse Aziendali
Altri contenuti su NRXP su Merlintrader trading Blog: NRXP – Approfondimento 1 | NRXP – Approfondimento 2 | NRXP – Analisi precedente